Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 4975-4983

  Stocks, Paul A ^a   Raynes, Kaylene J ^a   Bray, Patrick G ^a   Park, B Kevin ^a   O'Neill, Paul M ^a   Ward, Stephen A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ANTIMALARIAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CRYSTALLIZATION; DERIVATIZATION; DRUG POTENCY; MALARIA CONTROL; MULTIDRUG RESISTANCE; PARASITE SURVIVAL; PLASMODIUM FALCIPARUM; SYNTHESIS;

ANIMALS; ANTIMALARIALS; BINDING, COMPETITIVE; CHLOROQUINE; DRUG RESISTANCE; ERYTHROCYTES; HEMIN; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037038320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0108707     Document Type: Article

References (54)

1. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002, 415, 686-693.
2. Moon, R. P.; Tyas, L.; Certa, U.; Rupp, K.; Bur, D.; Jaquet, C.; Matile, H.; Loetscher, H.; Grueninger-Leitch, F.; Kay, J., Dunn, B. M.; Berry, C.; Ridley, R. G. Expression and Characterization of plasmepsin I from Plasmodium falciparum. Eur. J. Biochem. 1997, 244, 552-560.
3. See also Goldberg, D. E.; Slater, A. F. G.; Cerami, A. Haemoglobin degradation in malaria parasite Plasmodium falciparum. An ordered process in unique organelle. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 2931-2935.
4. Yayon, A.; Cabaantchik, Z.; Ginsburg, H. Identification of the acidic compartment of Plasmodium falciparum infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 1984, 3, 2695-2700.
5. Krogstad, D. J.; Sclesinger, P. H.; Gluzman, L. Y. Antimalarials increase vesilce pH in Plasmodium falciparum. J. Cell. Biol. 1985, 101, 2302-2309.
6. Goldberg, D. E.; Slater, A. F. G. The pathway of hemoglobin degradation in malaria parasites. Parasitol. Today 1992, 8, 280-283.
7. Rosenthal, P. J.; Meshnick, S. R. Hemoglobin catabolism and iron utilisation by malarial parasites. Mol. Biochem. Parasitol. 1996, 83, 131-139.
8. Ridley, R. G. Haemoglobin degradation and Fe(III)FPIX polymerization as antimalarial drug targets. J. Pharm. Pharmacol. 1997, 49 (2), 43-48.
9. Raynes, K. J.; Bray, P. G.; Ward, S. A.Altered binding of CQ to ferriprotoporpyrin IX is the basis for CQ resistance. Drug Res. Updates 1999, 2, 97-103.
10. Bray, P. G.; Jennah, O.; Raynes, K. J.; Mungthin, M.; Ginsburg, H.; Ward, S. A cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX is independent of NHE activity in Plasmodium falciparum. J. Cell. Biol. 1999,145, 363-376.
11. Warhurst, D. C. The quinine-Fe(III)FPIXin interaction and its relationship to antimalarial activity. Biochem. Pharmacol. 1981, 30, 3323-3327.
12. Slater, A. F. G.; Cerami, A. Inhibition by CQ of a novel Fe(III)-FPIX polymerase enzyme activity in malaria trophozoites. Nature 1992, 355, 167-169.
13. Atamna, H.; Ginsburg, H. Fe(III)FPIX degradation in the presence of glutathione. J. Biol. Cell. 1995, 270, 24876-24883.
14. Ginsburg, H.; Famin, O.; Zhang, J. M.; Krugliak, M. Inhibition of Glutathione-Dependent Degradation of Fe(III)FPIX by CQ and Amodiaquine as a Possible Basis for their Antimalarial Mode of Action. 1998, 56, 1305-1313.
15. Loria, P.; Miller, S.; Foley, M.; Tilley, L. Inhibition of the peroxidative degradation of Fe(III)FPIX as the basis of action of CQ and other quinoline antimalarials. Biochem. J. 1999, 339, 363-370.
16. Chou, A. C.; Chevli, R.; Fitch, C. D. Ferriprotoporphyrin IX fulfills the criteria for identification as the CQ receptor of malaria parasites. Biochemistry 1980, 19, 1543-1549.
17. Egan, T. J.; Ross, D. C.; Adams, P. A. Quinoline antimalarial drugs inhibit spontaneous formation of b-hematin (Malarial Pigment). FEBS Lett. 1996, 352, 54-57.
18. Dorn, A.; Stoffel, R.; Matile, H.; Bubendorf, A.; Ridley, R. G. Malarial Fe(III)FPIXozoin/b-Fe(III)FPIXatin supports Fe(III)-FPIX polymerization in the absence of protein. Nature 1995, 374, 269-271.
19. Raynes, K.; Foley, M.; Tilley, L.; Deady, L. W. Novel bisquinoline antimalarials: Synthesis, antimalarial activity and inhibition of Fe(III)FPIX polymerisation. Biochem. Pharmacol. 1996, 52, 551-559.
20. Bendrat, K.; Berger, B. J.; Cerami, A. Haem polymerisation in malaria. Nature 1995, 378, 138.
21. Sullivan, D. J., Jr.; Gluzman, I. Y.; Goldberg, D. E. Plasmodium hemozoin formation mediated by histidine rich proteins. Science 1996, 270, 219-222.
22. Bray, P. G.; Ward, S. A. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum. Pharmacol. Ther. 1998, 77, 1-28.
23. Ridley, R. G., Hofheinz, H.; Matile, H.; Jaquet, C.; Dorn, A.; Masciadri, R.; Jolidon, S.; Richter, W. F.; Guenzi, A.; Girometta, M. A.; Urwyler, H.; Huber, W.; Thiathong, S.; Peters, W. 4-Aminoquinoline analogues of CQ with shortened side chains retain activity against CQ resistant Plasmodium falciparum. Antimicrobial. Chemother. 1996, 40, 1846-1854.
24. (a) De, D.; Krogstad, F. M.; Cogswell, F. B.; Krogstad, D. J. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 1996, 55, 579-583.
25. (b) De, D.; Krogstad, F. M.; Byers, L. D.; Krogstad, D. J. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J. Med. Chem. 1998, 41, 4918-4926.
26. O'Neill, P. M.; Willock, D. J.; Hawley, S. R.; Bray, P. G.; Storr, R. C.; Ward, S. A.; Park, B. K. Synthesis, antimalarial activity and molecular modeling of tebuquine analogues. J. Med. Chem. 1997, 40, 437-448.
27. Raynes, K. J.; Stocks, P. A.; O'Neill, P. M.; Park, B. K.; Ward, S. A. New 4-aminoquinoline mannich base antimalarials 1. Effect of an alkyl substituent in the 5′-position of the 4′-hydroxylanilino side chain. J. Med. Chem. 1999, 42, 2747-2751.
28. Bray, P. G.; Hawley, S. R.; Mungthin, M.; Ward, S. A. Physiochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol. Pharmacol. 1996, 50, 1559-1566.
29. (a) O'Neill, P. M.; Hawley, S. R.; Storr, R. C.; Ward, S. A.; Park, B. K. The effect of fluorine substitution on the antimalarial activity of tebuquine. Bioorg. Med. Chem. Lett. 1996, 6, 391-392.
30. (b) Compounds 5 and 6 were originally reported in an earlier patent: Hofheinz, W.; Jaquet, C.; Jolidon, S. Methods of Treating Chloroquine-Resistant Malaria with Aminoquinoline Derivatives. United States Patent 5,596,002, 1997.
31. (c) For an extensive piece of work describing the synthesis of over 100 chloroquine analogues with activity against chloroquine resistant parasites, see Hofheinz, W.; Masciadri, R. Quinoline Derivatives for Treating Malaria. United States Patent, 5,948,-791, 1999.
32. (a) Hawley, S. R.; Bray, P. G.; O'Neill, P. M.; Park, B. K.; Ward, S. A. The role of drug accumulation in 4-aminoquinoline antimalarial potency. Biochem. Pharmacol. 1996, 52, 723-733.
33. (b) Vippagunata, S. R.; Dorn, A.; Ridley, R. G.; Vennerstrom, J. L. Characterisation of chloroquine-hematin Mu-Oxo dimer binding by isothermal titration calorimetry biochim. Biophys. Acta 2000, 1475, 133-140.
34. (c) Moreau, D.; Perly, B.; Biguet, J. Interactions between chloroquine and ferriprotoporphyrine IX. Nuclear magnetic-resonance study. Biochimie 1982, 64, 1015-1025.
35. (d) Egan, T.; Hunter, R.; Kaschula, C. H.; Marques, H. M.; Misplon, A.; Walden, J. Structure - Function relationships in aminoquinolines: Effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of b-hematin formation and antiplasmoidal activity. J. Med. Chem. 2000, 43, 283-291.
36. (e) Pandey, A. V.; Bisht, H.; Babbarwal, V. K.; Srivastav, J.; Pandey, K. C.; Chauhan, V. S. Mechanism of malarial haem detoxification inhibition by chloroquine. Biochem. J. 2001, 355, 333-338.
37. (f) Egan, T. J.; Mavuso, W. W.; Ross, D. C.; Marques, H. M. Thermodynamic factors controlling the interaction of quinoline antimalarial drugs with ferriprotoporphyrin IX. J. Inorg. Biochem. 1997, 68, 137-145.
38. (g) Sullivan, D. J.; Matile, H.; Ridley, R. G.; Goldberg, D. E. A. Common mechanism for blockade of heme polymerisation by antimalarial quinolines. J. Biol. Chem. 1998, 272, 31103-31107.
39. (h) Vippagunata, S. R.; Dorn, A.; Matile, H.; Bhattacharjee, A. K.; Karle, J. M.; Ellis, W. Y.; Ridley, R. G.; Vennerstrom, J. L. J. Med. Chem. 1999, 42, 4630-4639.
40. Trager, W.; Jenson, J. B. Human malaria parasites in continuous culture. Science 1976, 193, 673-675.
41. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by semi-automated microdilution technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.
42. MacIntryre, A. C.; Cutler, D. J. In vivo binding of CQ to rat muscle preparations. J. Pharm. Sci. 1986, 75, 1068-1070.
43. Yayon, A.; Cabantchik, Z. I.; Ginsburg, H. Susceptibility of human malaria parasites to CQ is pH dependent. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2784-2788.
44. Krogstad, D. J.; Sclesinger, P. H.; Gluzman, L. Y. Antimalarials increase vesicle pH in Plasmodium falciparum. J. Cell. Biol. 1985, 101, 2302-2309.
45. Ginsburg, H.; Nissani, E.; Krugliak, M. Alkanisation of the food vacuole of malarial parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity. Biochem. Pharmacol. 1989, 38, 2645-2654.
46. Fitch, C. D. Plasmodium falciparum in owl monkeys. Drug resistance and CQ binding capacity. Science 1970, 169, 289-290.
47. Fitch, C. D.; Yunis, N. G.; Chevli, R. High affinity accumulation of CQ by mouse erythrocytes infected with Plasmodium berghei. J. Clin. Invest. 1974, 54, 24-33.
48. Macomber, P. B., Sprinz, H.; Tousimis, A. J. Morphological effects of CQ on Plasmodium berghei in mice. Nature 1967, 214, 937-939.
49. Francis, S. E.; Sullivan, D. J.; Goldberg, D. E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Biochem. 1997, 51, 97-123.
50. Fitch, C. D. Chloroquine resistance in malaria: A deficiency of CQ binding. Proc. Natl. Acad. Sci. U.S.A. 1969, 64, 1181-1187.
51. Ginsburg, H.; Geary, T. Current concepts and new ideas on the mechanism of action of quinoline containing antimalarials. Biochem. Pharmacol. 1987, 36, 1567-1576.
52. Bray, P. G.; Mungthin, M.; Ridley, R.; Ward, S. A. Access to hematin: The basis of chloroquine resistance. Mol. Pharmacol. 1998, 54, 170-179.
53. Wang, S.; Kazanietz, M. G.; Blumberg, P. M.; Marquez, V. E.; Milne, G. W. A. Molecular modeling and site direction mutagenesis studies of phorbol ester-binding site in protein kinase C. J. Med. Chem. 1996, 39, 2541-2553.
54. As noted by one of the reviewers, the term "hemozoin" is used to describe the form of polymerized hematin produced by the parasite. While this material has the same composition as "β-hematin" produced in the laboratory, the physical state and the size of the crystals may be different. Therefore, in this paper, we have referred to hemozoin when describing parasite-derived material and β-hematin to describe the synthetic equivalent.